Congressionally Directed Medical Research Programs Military Operational Medicine Research Program/Joint Program Committee-5 Alcohol and Substance Abuse Research Program Consortium Award Funding Opportunity Number: W81XWH-14-ASARP-CA
Applications to the Fiscal Year 2014 (FY14) Alcohol and Substance Abuse Research Program (ASARP) are being solicited for the Defense Health Agency, Research, Development, and Acquisition (DHA RDA) Directorate, by the U.S. Army Medical Research Acquisition Activity (USAMRAA). As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the DHA RDA Directorate manages and executes the Defense Health Program (DHP) Research, Development, Test, and Evaluation appropriation. The Department of Defense (DoD) Congressionally Directed Medical Research Programs (CDMRP) operates in partnership with the Joint Program Committee 5/Military Operational Medicine Research Program (JPC-5/MOMRP) to provide oversight and execution management for the ASARP.
The goal of the ASARP is to identify and develop new medications to improve treatment outcomes for alcohol and substance use disorders (ASUD), especially as related to traumatic brain injury (TBI) and post-traumatic stress disorder (PTSD). The program encourages the use of collaborative, multidisciplinary approaches to accelerate the translation of basic research into clinical trial studies.
The program’s approach is to organize multidisciplinary, team-based translational research efforts to:
1. Identify promising compounds;
2. Conduct proof-of-principle basic research to determine which compounds are most appropriate for human research trials;
3. Conduct human proof-of-principle trials with promising compounds. This approach should accelerate the translation of contemporary basic science knowledge into enhanced clinical pharmacological treatment protocols for ASUD, including a regulatory strategy for U.S. Food and Drug Administration (FDA) compliance.
- Consortium Award – Letter of intent deadline February 26, 2015, full application is due March 5, 2015
- Must be an independent investigator at or above the level of Assistant Professor (or equivalent).
- Intended to support an ASUD-focused Consortium aimed at developing new medications to improve treatment outcomes, especially as related to traumatic brain injury (TBI) and post-traumatic stress disorder (PTSD)
- Objectives: (1) Identify promising compounds; (2) Conduct proof-of-principle basic research to determine which compounds are most appropriate for human research trials; Conduct human proof-of-principle trials with promising compounds. This approach should accelerate the translation of contemporary basic science knowledge into enhanced clinical pharmacological treatment protocols for ASUD, including a regulatory strategy for U.S. Food and Drug Administration (FDA) compliance
- The maximum period of performance is 5 years.
- The maximum allowable total costs for the entire period of performance are $10.8M of which only $3.6M is currently available.
- The applicant may request two options up to $3.6M in total costs each, to fund additional basic research projects, clinical trials, associated Management Core costs, and Consortium activities.
All applications must conform to the final Program Announcements and General Application Instructions that are available for electronic downloading from the Grants.gov website. A listing of all USAMRMC funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420.
Applications must be submitted through the federal government’s single-entry portal, Grants.gov. Requests for email notification of the Program Announcements release may be sent to help@eBRAP.org. For more information about the GWIRP or other CDMRP-administered programs, please visit the CDMRP website (http://cdmrp.army.mil).
Point of Contact:
Bookmark the CDMRP website:
Follow CDMRP on Twitter at:
View CDMRP research results on YouTube:
The Massachusetts Life Sciences Center’s Cooperative Research Matching Grant Program is providing funding of up to $250,000 per year for two years, for projects that advance “industry-academic research collaborations, support translational research, and accelerate the commercialization of promising products and services.” The industry partner is required to provide 1:1 matching funds.
Applications are due February 13th. http://www.masslifesciences.com/programs/crmg/
Any researchers interested in this opportunity should contact:
Director of Foundation Relations
Boston University School of Medicine
72 E. Concord Street, Suite L219
Boston, MA 02118
Pfizer’s Centers for Therapeutic Innovation (CTI) has announced a call for proposals for biotherapeutic targets. Areas of Interest include:
- Tissue remodeling
- Cancer Immunology
- Rare or genetic diseases
- Cardiovascular and metabolic diseases
Deadline: A 2-3 page pre-proposal is due 2/13/15.
The budget varies per project ranging $150,000-250,000 per year sponsored research.
For more details, please see the attached flyer and guidelines below.
Collaboration among Leading Lupus Organizations Continues with
Third Lupus Insight Prize – due March 19, 2015
The Lupus Research Institute (LRI) is proud to join once again with the Alliance for Lupus Research and Lupus Foundation of America to encourage scientific advances in lupus research. Now in its third year, the Lupus Insight Prize recognizes a major novel insight and/or discovery with the promise of changing thinking about lupus as well as a high likelihood of generating significant advances in diagnosis and treatment of the disease.
The Lupus Insight Prize recipient will be awarded $200,000 to be used for research dedicated to advancing understanding of the genetic, environmental, molecular, immunologic or cellular aspects of lupus and/or its treatment. The Prize must be utilized within three years from the date awarded.
LRI Scientific Advisory Board Member and Editor-in-Chief of Arthritis Research and Therapy Peter Lipsky, M.D. noted, “Lupus is a complex disease that requires out-of-the-box thinking to increase understanding and further our ability to treat persons with this disease effectively. Quantum leaps in understanding lupus will come from innovative discoveries by outstanding scientists. The Lupus Insight Prize will recognize those novel discoveries.”
The full application must be submitted by the Nominator and the Candidate electronically by March 19, 2015 at 5 p.m. ET. All applications will be reviewed by members of an independent Selection Committee comprised of representatives of the three funding lupus organizations. Instructions on how to submit a nomination for the Lupus Insight Prize and the complete guidelines are available at www.LupusInsightPrize.org. The 2015 Prize will be awarded by the three organizations at the Federation of Clinical Immunology Societies (FOCIS) annual meeting in San Diego this June.
The McKnight Endowment Fund for Neuroscience has selected four projects to receive the 2015 Memory and Cognitive Disorders Awards. The awards will total $1.2 million over three years for research on the biology of brain diseases, with each project receiving $300,000 between 2015 and 2017.
|Letters of intent for the 2016 awards are due by April 1, 2015.|
The Memory and Cognitive Disorders Awards support innovative research by U.S. scientists who are studying neurological and psychiatric diseases, especially those related to memory and cognition. The awards encourage collaboration between basic and clinical neuroscience to translate laboratory discoveries about the brain and nervous system into diagnoses and therapies to improve human health.
The awards will support studies of genes and areas of the brain involved in neurological disorders such as Alzheimer’s disease and other forms of dementia.
“Neurological diseases affect a vast segment of our aging population, including not only patients, but also their families and friends,” said Wendy Suzuki, PhD, chair of the awards committee and professor at New York University Center for Neural Science. “The long-term goal of these awards is to alleviate human suffering by thoroughly understanding the root causes of these diseases so that new clinical therapies can follow.”
The awards are inspired by the interests of William L. McKnight, who founded The McKnight Foundation in 1953 and wanted to support research on diseases affecting memory. His daughter, Virginia McKnight Binger, and The McKnight Foundation board established the McKnight neuroscience program in his honor in 1977.
ABOUT THE McKNIGHT ENDOWMENT FUND FOR NEUROSCIENCE
The McKnight Endowment Fund for Neuroscience is an independent organization funded solely by The McKnight Foundation of Minneapolis, Minnesota, and led by a board of prominent neuroscientists from around the country. The McKnight Foundation has supported neuroscience research since 1977. The foundation established the Endowment Fund in 1986 to carry out one of the intentions of founder William L. McKnight (1887-1978). One of the early leaders of the 3M Company, he had a personal interest in memory and its diseases.
The Endowment Fund makes three types of awards each year. In addition to the Memory and Cognitive Disorders Awards, they are the McKnight Technological Innovations in Neuroscience Awards, providing seed money to develop technical inventions to advance brain research; and the McKnight Scholar Awards, supporting neuroscientists in the early stages of their research careers.
For more information, see www.mcknight.org/neuroscience
St. Baldrick’s is a volunteer-driven charity committed to funding the most promising research to find cures for childhood cancers and give survivors long and healthy lives.
Grants are offered in seven funding categories for childhood cancer research:
- Post-Doctoral Fellowship for Childhood Cancer Research (Fellow)
- St. Baldrick’s Scholar (Career Development Award)
- St. Baldrick’s International Scholar (Career Development Award)
- Childhood Cancer Research Grant
- Consortium Research Grant
- Supportive Care Research Grant
- St. Baldrick’s Summer Fellows(Institutions with a pediatric oncology research summer fellowship program should review the updated 2015 Grant Guidelines for requirements and contact Grants@StBaldricks.org for more information on how to apply by the January 30 deadline.)
For more information contact:
(626) 792-8247, ext. 236
1333 South Mayflower Ave
Monrovia, CA 91016
McKnight Endowment Fund for Neurosciences
2015 McKnight Scholar Awards
These awards were established to encourage emerging neuroscientists to focus on disorders of learning and memory. Applicants for the McKnight Scholar Awards must demonstrate interest in solving important problems in relevant areas of neuroscience, including the translation of basic research to clinical neuroscience.
Deadline: January 7, 2015
In September 2014, BU’s Government Relations office hosted Michael Ledford, Vice President, Lewis-Burke Associates LLC, who delivered a presentation on the Department of Defense Health Research Programs.
The presentation covered current cross-cutting trends and priorities, specific DOD programs which engage most directly with university researchers, and techniques for navigating the DOD health landscape. The presentation reviewed more than 15 targets for research, including the Army Medical Research and Materiel Command, the Congressionally Directed Medical Research Program, the Defense Medical Research and Development Program, the Defense Advanced Research Projects Agency, and the Defense Threat Reduction Agency.
If you missed the live presentation, the slides and video from the event are now available for your viewing. Please note, you will need your Kerberos credentials to view both files.
The Dan David Prize, a joint international enterprise endowed by the Dan David Foundation and headquartered at Tel Aviv University, aims to foster universal values of excellence, creativity, justice, democracy, and progress and to promote the scientific, technological, and humanistic achievements that advance and improve our world. The Prize covers three time dimensions – Past, Present, and Future – that represent realms of human achievement. The Past refers to fields that expand knowledge of former times. The Present recognizes achievements that shape and enrich society today. The Future focuses on breakthroughs that hold great promise for improvement of our world.
The themes for the 2015 competition cycle are:
- Past – Retrieving the Past: Historians and their Sources
- Present – The Information Revolution
- Future – Bioinformatics
One million dollars per each field.
- Nominees may be individuals or organizations. Specific and unique projects may be included if the head of the project is a nominee.
- The individual or institution being nominated must have made a unique, profound contribution to humanity, on a global scale, in one of the selected fields.
- The work for which a nominee’s recognition is sought may represent a singular achievement, a series of achievements, or a life’s work.
- An individual or organization can only receive the Prize once for the same achievement and/or contribution.
- Self-nominations will not be accepted.
Sponsor Deadline: Sunday, November 30, 2014
Free to Breathe has a new funding opportunity solely focused on research to prevent or stop lung cancer metastasis. The foundation will only consider Letters of Intent proposing research to prevent or stop lung cancer metastasis including a clear vision and plan for clinical translation within three years.
- Letter of intent deadline: November 7th, 2014
- Invitation for submission of full application: January 7th, 2015
- Full application deadline: March 9th, 2015
- Applicant notification: May 15th, 2015
- Anticipated funding start date: June 1st, 2015
Visit the Free to Breathe website more information.